Notably, HKDC1 promotes tumor immune evasion during immunotherapy in hepatocellular carcinoma patients [6], and blocking HKDC1 prevents disease progression in hepatic carcinoma, T cell lymphoma, and lung adenocarcinoma [7, 8]. This evidence concerns the gene HKDC1 and neoplasm.